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Background: So far, the prevalence and risk factors for pulmonary hypertension (PH) diagnosed by
echocardiography in old and very old Chinese patients have not been reported. The purpose of the
present study was to evaluate the prevalence and potential risk factors for PH diagnosed by echocar-
diography in old and very old hospitalized patients.
Methods: One thousand and ninety-three hospitalized patients (80.76  9.77 years) were examined by
Doppler echocardiography for evaluating PH. PH was deﬁned by pulmonary artery systolic pressure
(PASP) 40 mmHg.
Results: One hundred and ﬁfteen patients (10.5%) of the old and very old patients were diagnosed with
PH. The prevalence of PH in patients who were 85 years old or older was 16.4%, which was higher than
other age groups. In the multivariate logistic regression analysis (forward stepwise procedure), age [odds
ratio (OR) ¼ 1.087, 95% conﬁdence interval (CI): 1.053e1.122, p < 0.001], chronic obstructive pulmonary
disease (COPD) (OR ¼ 1.704, 95% CI: 1.104e2.629, p ¼ 0.016), left ventricular systolic dysfunction
(OR ¼ 3.879, 95% CI: 1.726e8.719, p ¼ 0.001), and left ventricular diastolic dysfunction (OR ¼ 5.357, 95%
CI: 3.002e9.560, p < 0.001) were statistically signiﬁcant risk factors for PH (Table 2).
Conclusion: We concluded that the prevalence of PH in old and very old patients was high, especially in
patients with advanced age, COPD, and left ventricular dysfunction.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Pulmonary hypertension (PH) is a commonly encountered
health problem in elderly patients. Several studies revealed that the
prevalence of PH and mortality of PH in older patients may be
increasing1. However, the data on the prevalence and incidence of
PH in older patients is limited, because the current gold standard
for the assessment of PH is right heart catheterization (RHC)2,
which is associated with a small but signiﬁcant risk of severe
complications. Fortunately, there is uniform agreement that
Doppler echocardiography (DE) is the most acceptable method for
noninvasive estimation of PH3,4. The sensitivity and speciﬁcity oferest.
o, First Geriatric Cardiology
Road, Beijing 100853, China.
iwan Society of Geriatric EmergenDE for detecting PH ranged from 0.79 to 1.0 and from 0.68 to 0.98,
respectively5. One study demonstrated a signiﬁcant correlation
between DE and RHC (r¼ 0.96)6. Therefore, we assessed pulmonary
artery systolic pressure (PASP) by using DE.
Several studies demonstrated that PH is associated with cardiac
dysfunction1,7,8. Limited data are validated in the older population.
Thus, we evaluated the prevalence and risk factors specialized in
cardiac function for PH in older and very older hospitalized patients
by DE.2. Subjects and methods
2.1. Ethical approval of the study protocol
This study complied with the Declaration of Helsinki. It was
approved by the Scientiﬁc and Ethics Review Board of the Chinese
PLA General Hospital (Beijing, P.R. China). To be included in the
study, all patients provided written informed consent.cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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We enrolled 1093 patients from April 2007 to March 2011.
Patients were hospitalized for health examinations at the Geriatric
Division of the Chinese PLA General Hospital for 3e5 days. All
patientswereaged60yearsoldand lived in theWangshouluareaof
Beijing. We collected demographic data, laboratory testing data, and
the indication for theDE. Patientswere excluded fromanalysis if they
did not accept DE examination or if their data were not sufﬁcient for
analysis. In addition, dyslipidemia using American Heart Association
(AHA) criteria was deﬁned as serum triglyceride 150 mg/dL, total
cholesterol (TC) 200 mg/dL, low-density lipoprotein (LDL)-choles-
terol (LDL-C) 130 mg/dL, high-density lipoprotein (HDL)-choles-
terol (HDL-C) <40 mg/dL in men or <50 mg/dL in women9.
2.3. Echocardiography
The echocardiographic recordings of all patients were per-
formed by two experienced cardiac sonographers using 2.5e
4.0 MHz duplex probes and conventional equipment (Vivid 7; GE
Healthcare, Tampa, FL, USA). The echocardiographic data were
evaluated for cardiac chamber size, right atrial pressure (RAP), peak
tricuspid regurgitation jet velocities, ejection fraction, E wave, A
wave, and E/A ratio. DE estimation of PASP was calculated by using
the modiﬁed Bernoulli equation PASP¼ 4(V)2þ RAP, where V is the
peak velocity (in m/s) of the tricuspid valve regurgitant jet (TRV).
Assuming no obstruction to right ventricular outﬂow, right
ventricular systolic pressure equals PASP. RAP was estimated either
by inferior vena cava collapsibility, a standardized value (5 mmHg
or 10 mmHg), or a clinical estimation of jugular venous pressure10.
PH was deﬁned by PASP 40 mmHg by DE11.
Diastolic function was assessed in all patients using pulsed
Doppler peak E and A velocities, E/A ratio, deceleration time (DT),
and isovolumic relaxation time (IVRT). A septal and lateral E/E0 ratio
was derived from the peak E0 velocity using tissue Doppler imaging.
Diastolic function was categorized using mitral inﬂow and Doppler
Tissue Imaging parameters (according to the guidelines of the
American Society of Echocardiography, 2009)12. Grade 1 dysfunc-
tion (mild diastolic dysfunction) was deﬁned as an E/A ratio <0.8
and/or a DT >200 milliseconds; Grade 2 dysfunction (pseudo-
normal) was diagnosed where the E/A ratio was between 0.8 and
1.5, but either the E/E0 septal was 9 and 12 and/or the E/A ratio
decreased by 50% with Valsalva; Grade 3 diastolic dysfunction
(restrictive) was deﬁned as an E/A ratio >2 and/or DT <160 milli-
seconds and/or IVRT 60 milliseconds; the remaining patients
were deﬁned as having a normal diastolic function.
2.4. Blood sampling
Venous blood was collected following overnight fasting for at
least 12 hours to test uric acid, iron, total bilirubin, type B natri-
uretic peptide (BNP), and high-sensitivity C reactive protein (hs-
CRP). The serum urate level was determined photometrically by the
hydroxylamine method. Serum ferrum was tested by ferrous ben-
zoxazines directly using a colorimetric method. Serum total bili-
rubin levels were measured by the bilirubin oxidase method. BNP
was measured by immunoassay. Hs-CRP was tested using laser
nephelometry. All assays were processed within 2 hours of blood
sampling.
2.5. Statistical analyses
Continuous variables are mean  standard deviation. The
Student t test or ManneWhitney U two-sample tests (if the distri-
bution was not normal) were used to compare the continuousvariables between the two groups. Categorical data and proportions
were analyzed using the c2 test. A p value <0.05 was considered
signiﬁcant. Parameters signiﬁcantly related to the presence of PH
were determined using binary logistic regression analyses (SPSS
version 14.0 for Windows; SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Patient characteristics
There were no signiﬁcant differences between the PH group and
the control group when comparing age, being a current smoker, or
having hypertension, cerebrovascular disease, or peripheral arterial
occlusive disease. The number of patients having coronary artery
disease, heart dysfunction, or chronic obstructive pulmonary
disease (COPD), taking angiotensin-converting enzyme inhibitor
(ACEI) drugs, and having higher nitrates was signiﬁcantly higher in
patients with PH than in patients without PH (p< 0.05). The control
group was more likely to complicate with dyslipidemia (p < 0.05).
Age, BNP levels, left atrial dimension, and right ventricular
dimension were signiﬁcantly higher in patients with PH (p < 0.05).
Serum ferrum levels, ejection fraction, and fractional shortening
were signiﬁcantly higher in patients without PH compared with PH
patients (p < 0.05) (Table 1).
3.2. The prevalence of PH
One hundred and ﬁfteen patients (10.5%) of the old and very old
patients were diagnosed with PH. The prevalence of PH demon-
strated an increasing trend with advancing age. The prevalence of
PH in patients whowere 85 years old or older was 16.4%, which was
higher than other age groups (Fig. 1).
3.3. Multiple logistic regression analysis
In the multivariate logistic regression analysis (forward step-
wise procedure), age [odds ratio (OR) ¼ 1.087, 95% conﬁdence
interval (CI): 1.053e1.122, p < 0.001], COPD (OR ¼ 1.704, 95% CI:
1.104e2.629, p ¼ 0.016), left ventricular systolic dysfunction
(OR ¼ 3.879, 95% CI: 1.726e8.719, p ¼ 0.001), and left ventricular
diastolic dysfunction (OR ¼ 5.357, 95% CI: 3.002e9.560, p < 0.001)
were statistically signiﬁcant risk factors for PH (Table 2).
4. Discussion
The prevalence of PH in this study was 10.5% in old and very old
patients. Rich and his colleague demonstrated that the prevalence
of PH in men above the age of 64 years was 28.2% by using chest
radiograph (CR) criteria in a population of 10,000 subjects entered
into the Second National Health and Nutrition Examination
Survey13. The prevalence of the present study was lower than the
study by Rich, which may be associated with different methods for
detecting PH. When compared with catheterization data, CR lacks
sufﬁcient sensitivity and speciﬁcity as a screening test for PH14. We
evaluated the prevalence of PH by using DE, which is currently
recommended to be the noninvasive screening test of choice for
detecting PH. Additionally, the prevalence of PH for different
conditions from studies in China ranged from 3.8% to 47%. Among
106,640 hospitalized patients, 7085 (6.6%) patients were diagnosed
with PH15. This ﬁgure is similar to the outcome in the present study.
The present study showed that age is a statistically signiﬁcant
risk factor for PH. The prevalence of PH in patients, who were 85
years old or older, was 16.4%, which was higher than other age
groups. Leunget al7 also showed that PHwas signiﬁcantlyassociated
with age 80 years. Moreover, one study, by Hyduk and his
Table 1
Patient demographics.
All patients (n ¼ 1093) Patients with PH (n ¼ 115) Patients without PH (n ¼ 978) p
Age (years) 80.76  9.77 86.12  6.30 80.13  9.91 0.001
Female 42 (3.8%) 6 (5.2%) 36 (3.6%) 0.417
Hypertension 803 (73.5%) 86 (74.7%) 717 (73.3%) 0.735
Dyslipidemia 297 (27.1%) 21 (18.2%) 276 (28.2%) 0.023
History of coronary artery disease 736 (67.3%) 91 (79.1%) 645 (66%) 0.004
Cerebrovascular disease 320 (29.2%) 36 (31.3%) 284 (29%) 0.613
Diabetes 412 (37.7%) 43 (37.4%) 369 (37.7%) 0.943
PAOD 93 (8.5%) 12 (10.4%) 81 (8.3%) 0.433
COPD 311 (28.5%) 57 (49.6%) 254 (26%) 0.001
BMI (kg/m2) 24.78  11.85 23.69  3.36 24.91  12.46 0.324
Current smoker 94 (8.6%) 7 (6.1%) 87 (8.9%) 0.309
Left ventricular systolic dysfunction (%) 37 (3.3%) 12 (10.4%) 25 (2.5%) 0.001
Left ventricular diastolic dysfunction (%) 710 (64.9%) 99 (86%) 611 (62.4%) 0.001
Left ventricular ejection fraction (%) 60.76  5.11 58.25  6.13 61.06  4.89 0.001
Shortening fraction (%) 33.30  2.87 32.19  2.880 33.43  2.81 0.001
Left atrial dimension (mm) 37.05  4.23 39.48  4.57 36.46  4.10 0.001
Left ventricular end-diastolic dimension (mm) 48.70  3.95 48.43  5.04 48.74  3.80 0.434
Right ventricular dimension (mm) 35.24  2.41 37.03  2.80 35.02  2.27 0.001
Left ventricular end-diastolic volume (mL) 112.70  21.06 112.06  28.81 112.77  19.94 0.730
Uric acid (mmol/L) 334.47  123.25 319.00  117.21 335.13  123.88 0.200
Serum ferrum (mmol/L) 15.05  6.66 13.58  8.38 15.23  6.40 0.017
Total bilirubin (mmol/L) 10.32  10.93 11.53  13.52 10.19  10.60 0.232
BNP (pg/mL) 205 (80e591) 558 (236e1427) 174 (72e474) 0.001
Hs-CRP (mg/dL) 2.15  6.67 2.69  5.40 2.08  6.81 0.408
Medications taken
CCBs 537 (49.1%) 54 (47%) 483 (49.4%) 0.622
ACEIs 121 (11.1%) 19 (16.5%) 102 (10.4%) 0.048
ARBs 328 (30%) 30 (26.1%) 298 (30.5%) 0.331
Statins 221 (20.2%) 16 (13.9%) 205 (21%) 0.075
Beta-adrenoceptor blockers 366 (33.5%) 46 (40%) 320 (32.7%) 0.117
Nitrates 619 (56.6%) 76 (66.1%) 543 (55.5%) 0.030
ACEIs¼ angiotensin-converting enzyme inhibitors; ARBs¼ angiotensin receptor blockers; BMI¼ bodymass index; BNP¼ type-B natriuretic peptide; CCBs¼ calcium-channel
blockers; COPD ¼ chronic obstructive pulmonary disease; Hs-CRP ¼ high-sensitivity C-reactive protein; PAOD ¼ peripheral arterial occlusive disease.
D.-Y. Chen et al.104colleague, demonstrated that the proportion of patients 75 years
old dying with PH was 30%, and age-speciﬁc death rates for PH
increased with aging16. These ﬁndings were consistent with the
results in this study. Interestingly, Al-Shaer et al17 have suggested
that normal aging may induce signiﬁcant global vascular dysfunc-
tion due to decreased activity of endothelial nitric oxide synthase
(eNOS). A recent study suggested that increased retrograde and
oscillatory shear in peripheral conduit arteries with aging is asso-
ciated with the reduction of NO biavailability18. In addition, aging is
also associated with an attenuation in the regenerative capacity of
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Fig. 1. The prevalence of pulmonary hypertension (PH) among age groups. *The prev-
alence of patients85 years oldwas higher than other age groups (p< 0.05). **The group
of 65 years of age or older on prevalence was lower than other groups (p < 0.05).by an increased rate of endothelial cell apoptosis, increased forma-
tion of oxygen-derived free radicals, upregulation of inducible nitric
oxide synthase (iNOS), and defective repair mechanisms of endo-
thelia19,20. Furthermore, an excellent review by Nayak et al
summarized that thereductionofNOmayresult inelevatingvascular
tone, promoting platelet aggregation, and attenuating ET-1 disinhi-
bitionandvascularendothelial growth factorgeneexpression,which
may all subject elderly adults to increased vulnerability to develop
PH21. These ﬁndings suggest that endothelial dysfunction may play
an inevitable role in the development of PH in older patients.
The present study showed that COPD patients were at a great
risk for developing PH. The prevalence of PH in COPD patients was
18.3% (57/311), and about 50% of patients with PH have a history of
COPD in the present study. However, one study by Fayngersh et al3
found that the frequency of PH detected by echocardiogram was
60% (63/105) in stable COPD outpatients and elderly patients; those
with more airway obstruction were at higher risk for developing
PH. The prevalence of PH in COPD patients in the study of Fayngersh
et al was higher than the present study, which could be because the
tools for evaluating PH in the present study were stricter than the
former (PASP40 mmHg vs. PASP36 mmHg). PH was common in
COPD, which could be associated with vasoconstriction and
remodeling of pulmonary arteries. Hypoxia, inﬂammation, and the
toxic effects of cigarette smoke can be considered to be conﬁrmed
factors for PH in COPD patients22.
The present study revealed that left ventricular dysfunctionwas
a statistically signiﬁcant risk factor for PH. Leung et al7 demon-
strated that of 455 patients with left ventricular diastolic
dysfunction, 239 (52.5%) had PH and left ventricular end-diastolic
pressure 25 mm Hg was strongly and independently associated
with PH (OR ¼ 4.3). Abnormalities in diastolic function may result
in increased pressure of the left atrium and pulmonary veins, which
Table 2
Results of the multiple logistic regression analysis.
B SE Wald df Signiﬁcance Exp (B) 95% CI for EXP (B)
Lower Upper
Age 0.084 0.016 26.937 1 0.000 1.087 1.053 1.122
COPD 0.533 0.221 5.805 1 0.016 1.704 1.104 2.629
Left ventricular systolic dysfunction 1.356 0.413 10.767 1 0.001 3.879 1.726 8.719
Left ventricular diastolic dysfunction 1.678 0.295 32.273 1 0.000 5.357 3.002 9.560
Constant 10.761 1.410 58.235 1 0.000 0.000
B ¼ Beta; CI ¼ conﬁdence interval; df ¼ degrees of freedom; SE ¼ standard error.
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pressure in the pulmonary arteries1. Moreover, a study showed that
after 28-month follow-up, the patients with a high velocity of
tricuspid regurgitation had a highermortality rate than the patients
with a low velocity (57% vs. 17%) in 108 patients with dilated
cardiomyopathy8. The percentages of hospitalizations or death
from the former were higher than for the latter (89% vs. 32%)8.
Despite the association of left ventricular systolic dysfunction with
PH, the relationship between left ventricular ejection fraction and
PH is not clear23. The present study also found that left ventricular
ejection fraction is associated with PH. These ﬁndings suggested
that PH was associated with left ventricular dysfunction and tar-
geting these risk factors could possibly attenuate the development
of PH.
There are mainly two limitations in this study. First, the present
study was a nonrandomized retrospective study. Second, there
were fewer female patients in this study.
In conclusion, these ﬁndings suggest that a signiﬁcant number
of old and very old hospitalized patients are diagnosed with PH.We
found that the prevalence of PH in old and very old hospitalized
patients was high, especially in patients with old age, COPD, and left
ventricular dysfunction. Therefore, we should pay more attention
to these patients and target risk factors, which could possibly
attenuate the development of PH.Acknowledgments
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